[Newsmp] After the Omicron variant swept the world in the first quarter, the sales of COVID-19 related products are also passing the peak.Newsmp tallied the global pharmaceutical companies’ second-quarter reports and found that the sales of major COVID-19 treatments and vaccines fell significantly f

[Newsmp] In July, foreign ownership of pharmaceutical stocks related to COVID-19 treatments decreased significantly.According to the Korea Exchange, 22 of the 46 pharmaceutical index stocks rose in July, while 22 stocks fell.Foreign ownership in Ildong Pharmaceutical and Ildong Holdings plunged 4.37

[Newsmp] South Korea’s bio-health industry, which had been soaring, grew negatively for the first time this year. However, pharmaceutical products exports continued to grow in double digits for eight consecutive months.According to the Ministry of Trade, Industry and Energy, exports of bio-health pl

[Newsmp] The atmosphere of the listed pharmaceutical companies, whose closing accounts are in December, is hot as they have begun to announce their second-quarter earnings.On the 20th, Hanmi Pharmaceutical was the first to announce its tentatively counted second quarter result, and on the 27th, six

[Newsmp] Stock market consensus toward major top pharmaceutical companies is fluctuating ahead of the Q2 earnings announcement.While Hanmi Pharmaceutical earlier released its report that greatly exceeds the consensus as if it protested the negative gaze of the stock market, the consensus of other to

[Newsmp] Japanese pharmaceutical companies operating in Korea all ramped up their retained earnings last year.The audit reports showed that the retained earnings of the nine Japanese pharmaceutical companies’ Korean offshoots have increased.Among them, Eisai Korea saw its retained earnings rise by K

[Newsmp] Last year, the average sales growth rate of Japanese pharmaceutical companies operating in Korea was only 1.4%. Operating profit increased by only 6.2%.In particular, the sluggishness of big companies was noticeable. Among them, the first to third place in sales in 2020 (business year) show

[Newsmp] While Korea’s consumer price index (CPI) is on the rise, there is no significant change in the pharmaceutical products’ CPI.Even so, the CPI of anti-inflammatory drugs, oriental medicine, and cold medicines, which had been out of stock after vaccination, accelerated.Statistics Korea said th

[Newsmp] In June, foreigners’ stake in Ildong Pharmaceutical ramped up more than 5%p.According to the Korea Exchange, as of the end of June, foreign ownership of Ildong Pharmaceutical stood at 8.15%, up 5.61%p from the end of the previous month.Foreign ownership in Ildong Holdings and Bukwang Pharma

[Newsmp] Exports of the bio-health industry, which maintained double-digit growth this year, slowed significantly in June. On the other hand, pharmaceutical exports expanded, reaching the 50% growth level.According to the Ministry of Trade, Industry and Energy, exports of the bio-health industry ros

[Newsmp] A study has shown that varenicline (trade name Champix, Pfizer), a medication that aids in smoking cessation, is effective in quitting smoking in patients with type 2 diabetes. On the 21st (local time), the JAMA Network Open, a journal of the American Medical Association, published the resu

[Newsmp] In the first half, DPP-4 inhibitors and SGLT-2 inhibitors accounted for more than half of the drugs approved by the Ministry of Food and Drug Safety (MFDS).A total of 879 drugs received MFDS approval in South Korea by the 22nd of this year, of which 449 drugs were DPP-4 inhibitors or SGLT-2

[Newsmp] Exports in the bio-health sector have increased by more than 20% this year, ranking the top 10.The Korea International Trade Association published a report Tuesday, assessment of imports and exports during the first half of 2022 and projections for the second half.In its report, from Januar

[Newsmp] The trade deficit for medicinal and pharmaceutical products (SITC54) was close to the $3 billion mark in five months, far exceeding the annual deficit last year.Exports of medicinal and pharmaceutical products (SITC54) have shrunk to more than 60% for the fifth consecutive month this year,

[Newsmp] In April, pharmaceutical products exports fell below $500 million, but rose again to the $600 million mark in a month.Exports of diagnostic reagents, which exceeded $500 million for three consecutive months at the beginning of the year and fell to the $200 million mark in April, also recove

[Newsmp] Although daily life contracted again in the first quarter as the Coronavirus Omicron variant flourished, listed pharmaceutical companies’ spending on entertainment increased significantly.Newsmp compiled the quarterly reports of pharmaceutical companies that included entertainment expenses,

[Newsmp] In May, monthly exports of pharmaceutical products once again exceeded $1 billion.The Ministry of Trade, Industry and Energy announced on June 1 that bio-health exports among the 15 major industries reached $1.5 billion in May, up 24.6% year-on-year.With a double-digit growth rate for five

[Newsmp] GLP-1 RA Ozempic (Novo Nordisk), which should be taken once a week, was on a par with the front runner Trulicity (Lilly).While major guidelines began to prefer GLP-1 RA over basal insulin, the first oral GLP-1 RA product Rybelsus (Novo Nordisk) is poised to surpass the second-generation bas

[Newsmp] The amount of cash equivalents of listed pharmaceutical companies decreased slightly in the first quarter.Among them, Dong-A ST rose to the KRW 200 billion mark, surpassing Yuhan Corporation, which retreated from KRW 200 billion.Newsmp compiled the cash & cash equivalent of the 64 listed ph

[Newsmp] Despite listed pharmaceutical companies posting double-digit sales growth in the first quarter, the combined retained earnings decreased slightly.Newsmp compiled the retained earnings of the listed pharmaceutical companies whose closing accounts are in NovemberㆍDecember and found that retai